Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis - 13/12/18
Doi : 10.1016/j.jaad.2018.09.002
Mark G. Lebwohl, MD a, ⁎ 
, Jeffrey L. Sugarman, MD, PhD b, Linda Stein Gold, MD c, David M. Pariser, MD d, Tina Lin, PharmD e, Radhakrishnan Pillai, PhD f, Gina Martin, MOT f, Susan Harris, MS g, Robert Israel, MD g
, Jeffrey L. Sugarman, MD, PhD b, Linda Stein Gold, MD c, David M. Pariser, MD d, Tina Lin, PharmD e, Radhakrishnan Pillai, PhD f, Gina Martin, MOT f, Susan Harris, MS g, Robert Israel, MD g a Icahn School of Medicine at Mount Sinai, New York, New York
b University of California, San Francisco, California
c Henry Ford Hospital, Detroit, Michigan
d Virginia Clinical Research Inc, Norfolk, Virginia
e Ortho Dermatologics, Bridgewater, New Jersey
f Dow Pharmaceutical Sciences Inc (division of Valeant Pharmaceuticals, North America LLC), Petaluma, California
g Valeant Pharmaceuticals, Bridgewater, New Jersey
∗Correspondence to: Mark G. Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY 10029Icahn School of Medicine at Mount SinaiNew YorkNY10029
| Funding sources: Supported by Valeant Pharmaceuticals North America LLC. |
|
| Conflicts of interest: Dr Lebwohl is an employee of Mount Sinai which receives research funds from: Abbvie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen / Johnson & Johnson, Leo Pharmaceutucals, Medimmune/Astra Zeneca, Novartis, Pfizer, Sciderm, UCB, Valeant, and ViDac. Dr Lebwohl is also a consultant for Allergan, Aqua, Arcutis, Boehringer-Ingelheim, LEO Pharma, Menlo, Promius, and Verrica. Please note that all companies are the US subsidiaries except for Boehringer-Ingleheim (Germany) and Medimmune/AstraZeneca (United Kingdom). Dr Sugarman ia a consultant for Ortho Dermatologics, Verrica, Regeneron and a speaker for Pfizer. Dr Gold is an advisor, consultant and speaker for Valeant Pharmaceuticals. Dr Pariser is a consultant, investigator, or advisor for Bickel Biotechnology, Biofrontera, Celgene, Dermira, DUSA Pharmaceuticals, Leo, Novartis, Pfizer, Promius, Regeneron, Sanofi, TherVida, Valeant, Abbott, Asana Biosciences, Dermavant, Eli Lilly, Merck, Novo Nordisk, Ortho Dermatologics, Peplin, Photocure, and Steifel. Dr Lin, Ms Harris, Dr Pillai, Ms Martin, and Dr Israel are employees of Valeant Pharmaceuticals. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 1
P. 282-285 - janvier 2019 Retour au numéro
Article précédent
- Growth in the cost of biologics in Medicare beneficiaries, 2013 to 2016
- Partik Singh, Jonathan I. Silverberg
- Assessment of clinician accuracy for diagnosing melanoma on the basis of electrical impedance spectroscopy score plus morphology versus lesion morphology alone
- Ryan M. Svoboda, Giselle Prado, Rachel S. Mirsky, Darrell S. Rigel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?